There are 2789 resources available
453P - Routine DPYD mutation testing for patients receiving fluoropyrimidines for gastrointestinal (GI) cancers: Real world experience in a tertiary UK oncology centre
Presenter: David Lau
Session: ePoster Display
454P - CCR5/CCL5 gene expression in colorectal cancer (CRC): Comprehensive profiling and clinical value
Presenter: Francesca Battaglin
Session: ePoster Display
455P - Concordance of baseline RAS mutational status (ms) between tissue and cell-free DNA (cfDNA) and association with overall response rate (ORR) in first-line (1L) metastatic colorectal cancer (mCRC) patients (pts): PERSEIDA study (cohort 2) (NCT02792478)
Presenter: Manuel Valladares-Ayerbes
Session: ePoster Display
456P - Prognostic and predictive value of tumor-infiltrating lymphocytes in combination with systemic inflammatory markers in colon cancer
Presenter: Safa Can Efil
Session: ePoster Display
457P - Circulating tumor DNA (ctDNA) from patients (pts) with advanced colorectal cancer (CRC) is enriched for EGFR extracellular domain (ECD) mutations
Presenter: Sabine Tejpar
Session: ePoster Display
263P - Predicting bevacizumab efficacy in mTNBC
Presenter: Heba Bakri
Session: ePoster Display
264P - AMEERA-1: Subgroup analyses of phase I/II study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC)
Presenter: Sarat Chandarlapaty
Session: ePoster Display
267P - Phase Ib/II open-label, randomized evaluation of second- or third-line (2L/3L) atezolizumab (atezo) + entinostat (entino) in MORPHEUS-HR+ breast cancer (M-HR+BC)
Presenter: Amir Sonnenblick
Session: ePoster Display